Despite the ongoing prevalence of dengue fever in Taiwan, the primary method of epidemic prevention in our country still relies on traditional mosquito spray.
AMS BioteQ collaborates with Professor Sheng-Fan Wang, Director of the Center for Tropical Medicine and Infectious Diseases Research at Kaohsiung Medical University
As the prices of eggs and chicken soar, avian influenza is posing a significant challenge to human society. The virus, which used to be limited to birds, has recently been reported to infect humans.
Another Breakthrough in Epidemic Prevention! The Team at Kaohsiung Medical University Has Developed a COVID-19 Antibody Testing Platform for Precise Assessment of Antibody Efficacy
AMS BioteQ Chairman, Dr. Yi-Ju Tsai (center), and the team are actively conducting research to develop potential new drugs and address the unmet topical medication market. Antibiotic-Resistant Superbug – one of the greatest threats to human health.
AMS BioteQ focuses its research and development efforts on three key stages: “novel compound development,” “patent in research and development technology,” and “new drug research and development.”
In the research and development of oral medication for Wuhan pneumonia (novel coronavirus disease, COVID-19), the Taiwanese biotechnology industry is actively involved.
As the COVID-19 pandemic subsides, there’s positive news regarding the first antibiotic developed by a Taiwanese biotech company to inhibit the coronavirus.